X0306 4 2016-01-11 0 0001435049 ADURO BIOTECH, INC. ADRO 0001635616 Brockstedt Dirk G. C/O ADURO BIOTECH, INC. 626 BANCROFT WAY, 3C BERKELEY CA 94710 0 1 0 0 Sr. VP of Research and Dev. Common Stock 2016-01-11 4 M 0 956 1.45 A 12956 D Common Stock 2016-01-11 4 S 0 956 23.51 D 12000 D Common Stock 2016-01-11 4 M 0 21044 0.45 A 33044 D Common Stock 2016-01-11 4 S 0 18638 21.57 D 14406 D Common Stock 2016-01-11 4 S 0 1706 22.40 D 12700 D Common Stock 2016-01-11 4 S 0 700 23.29 D 12000 D Stock Option (Right to Buy) 1.45 2016-01-11 4 M 0 956 0.00 D 2025-01-09 Common Stock 956 290106 D Stock Option (Right to Buy) 0.45 2016-01-11 4 M 0 21044 0.00 D 2020-03-18 Common Stock 21044 51195 D The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $22.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.01 to $23.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.10 to $23.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015. The shares subject to the Option are fully vested and immediately exercisable. /s/ Jennifer Lew, Attorney-in-Fact 2016-01-11